DEPARTMENT OF CARDIOLOGY

| UHID / IP NO | 40008253 (16390) | RISNo./Status: | 4016827/ |
|----------------|---|----------------------|----------|
| Patient Name: | Mr. MOHAN LAL MEENA | Age/Gender: | 44 Y/M |
| Referred By: | Dr. DIWANSHU KHATANA | Ward/Bed No: | OPD |
| Bill Date/No : | 09/12/2023 12:25PM/ OPSCR23- 24/9036 | Scan Date : | |
| Report Date: | 09/12/2023 3:47PM | Company Name: | Final |

REFERRAL REASON: HEALTH CHECKUP

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

| Normal Normal | | | | | | | | |
|---------------|------------|----------------|--------|---------|----------|-----------------|---------------|---------|
| IVSD | 9.6 | 6-12mm | | | LVIDS | 30.8 | 20-40mm | |
| LVIDD | 46.2 | | 32- | 57mm | | LVPWS | 16.4 | mm |
| LVPWD | 9.6 | 6-12mm | | | AO | 30.3 | 19-37mm | |
| IVSS | 15.9 | |] | mm | | LA | 34.2 | 19-40mm |
| LVEF | 62-64 | | > | 55% | | RA | • | mm |
| | DOPPLER | R MEA | ASUREN | IENTS & | & CALC | ULATIONS | <u>:</u> | |
| STRUCTURE | MORPHOLOGY | VELOCITY (m/s) | | | GRADIENT | | REGURGITATION | |
| | | | | | | (mmHg) | | |
| MITRAL | NORMAL | E | 1.14 | e' | - | - | | NIL |
| VALVE | | A | 0.81 | E/e' | - | | | |
| TRICUSPID | NORMAL | | E | 0. | 78 | - | | NIL |
| VALVE | | | A | 0. | 68 | - | | |
| | | | А | 0. | 00 | | | |
| AORTIC | NORMAL | 1.43 | | | - | | NIL | |
| VALVE | | | | | | | | |
| PULMONARY | NORMAL | 1.01 | | | | | NIL | |
| VALVE | | | | | | - | | |

COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

DEPARTMENT OF RADIO DIAGNOSIS

| UHID / IP NO | 40008253 (16390) | RISNo./Status: | 4016827/ |
|----------------|---|----------------------|--|
| Patient Name: | Mr. MOHAN LAL MEENA | Age/Gender: | 44 Y/M |
| Referred By: | Dr. DIWANSHU KHATANA | Ward/Bed No: | OPD |
| Bill Date/No : | 09/12/2023 12:25PM/ OPSCR23- 24/9036 | Scan Date : | |
| Report Date : | 09/12/2023 2:07PM | Company Name: | Mediwheel - Arcofemi Health Care Ltd. |

ULTRASOUND STUDY OF WHOLE ABDOMEN

Liver: Normal in size & echotexture. No obvious significant focal parenchymal mass lesion

noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.

Gall Bladder: Lumen is clear. Wall thickness is normal. CBD is normal.

Pancreas: Normal in size & echotexture.

Spleen: Normal in size & echotexture. No focal lesion seen.

Right Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or

obstructive calculus noted.

Left Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or

obstructive calculus noted.

Urinary Bladder: Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Mild

diffuse wall thickening seen.

Prostate: Is normal in size, measuring approx. 18cc in volume. **Others:** No significant free fluid is seen in pelvic peritoneal cavity.

IMPRESSION: USG findings are suggestive of

• Diffuse urinary bladder wall thickening.

Correlate clinically & with other related investigations.

DR. APOORVA JETWANI

Incharge & Senior Consultant Radiology

MBBS, DMRD, DNB Reg. No. 26466, 16307

Mr. MOHAN LAL MEENA **Patient Name** Lab No 583685

UHID 330611 **Collection Date** 09/12/2023 3:11PM 09/12/2023 3:14PM Age/Gender **Receiving Date** 44 Yrs/Male **Report Date IP/OP Location** O-OPD 09/12/2023 4:00PM

Referred By Dr. EHCC Consultant Final

Report Status



BIOCHEMISTRY

| Test Name | Result | Unit | Biological Ref. Range |
|-----------|--------|------|---|
| | | | Sample: WHOLE BLOOD EDTA |
| HBA1C | 5.4 | % | < 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes |
| | | | Known Diabetic Patients < 7 % Excellent Control 7 - 8 % Good Control > 8 % Poor Control |

Method: - High - performance liquid chromatography HPLC Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbAlC and mean blood glucose values during the preceding 2 to 3 months.

End Of Report

RESULT ENTERED BY : Mr. Ravi Summa Sing.

Mobile No.

9773349797

Dr. SURENDRA SINGH **CONSULTANT & HOD** MBBS|MD| PATHOLOGY

Dr. ASHISH SHARMA **CONSULTANT & INCHARGE PATHOLOGY** MBBS | MD | PATHOLOGY

Page: 1 Of 1

Patient NameMr. MOHAN LAL MEENALab No583685

UHID 330611
Age/Gender 44 Yrs/Male
IP/OP Location O-OPD

Referred By

Mobile No.

 Receiving Date
 09/12/2023 3:14PM

 Report Date
 09/12/2023 4:27PM

09/12/2023 3:11PM

Report Status Final

Collection Date

भारत ।

BIOCHEMISTRY

Test Name Result Unit Biological Ref. Range

Sample: Serum

PSA (TOTAL) 0.416 ng/mL 0.00 - 4.00

Total (Free + complexed) PSA - Prostate specific antigen (tPSA)
Method: FlectroChemiluminescence ImmunoAssay - FCLIA

Dr. EHCC Consultant

9773349797

Method: ElectroChemiLuminescence ImmunoAssay - ECLIA
Interpretation:-PSA determinations are employed are the monitoring of progress and efficiency of therapy in patients with prostate carcinoma or receiving hormonal therapy.

End Of Report

RESULT ENTERED BY: CHHITAR MALKUMAWAT

Summer Sign.

Dr. SURENDRA SINGH CONSULTANT & HOD MBBS | MD | PATHOLOGY Dr. ASHISH SHARMA
CONSULTANT & INCHARGE PATHOLOGY
MBBS|MD| PATHOLOGY

Page: 1 Of 1

Patient Name Mr. MOHAN LAL MEENA Lab No 4016827 UHID 40008253 **Collection Date** 09/12/2023 12:56PM 09/12/2023 1:19PM Age/Gender 44 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 09/12/2023 5:45PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final

Mobile No. 9610884892

BIOCHEMISTRY

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: Fl. Plasma

 BLOOD GLUCOSE (FASTING)
 100.0
 mg/dl
 74 - 106

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP) 152.1 mg/dl Non – Diabetic: - < 140 mg/dl

Pre – Diabetic: - 140-199 mg/dl Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

THYROID T3 T4 TSH Sample: Serum

| Т3 | 1.600 | ng/mL | 0.970 - 1.690 |
|-----|-------|--------|---------------|
| T4 | 9.51 | ug/dl | 5.53 - 11.00 |
| TSH | 3.15 | μIU/mL | 0.40 - 4.05 |

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

| Patient Name | Mr. MOHAN LAL MEENA | Lab No | 4016827 |
|---------------------------|----------------------|-----------------|--------------------|
| UHID | 40008253 | Collection Date | 09/12/2023 12:56PM |
| Age/Gender IP/OP Location | 44 Yrs/Male | Receiving Date | 09/12/2023 1:19PM |
| | O-OPD | Report Date | 09/12/2023 5:45PM |
| Referred By | Dr. DIWANSHU KHATANA | Report Status | Final |
| Mobile No. | 9610884892 | | |

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

1.8

24.4

Interpretation: - The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

| LFT (LIVER FUNCTION TEST) | | | | Sample: Serum |
|---------------------------|------|-------|-------------|---------------|
| BILIRUBIN TOTAL | 0.82 | mg/dl | 0.00 - 1.20 | |
| BILIRUBIN INDIRECT | 0.66 | mg/dl | 0.20 - 1.00 | |
| BILIRUBIN DIRECT | 0.16 | mg/dl | 0.00 - 0.40 | |
| SGOT | 26.2 | U/L | 0.0 - 40.0 | |
| SGPT | 24.1 | U/L | 0.0 - 40.0 | |
| TOTAL PROTEIN | 7.9 | g/dl | 6.6 - 8.7 | |
| ALBUMIN | 5.1 | g/dl | 3.5 - 5.2 | |
| GLOBULIN | 2.8 | | 1.8 - 3.6 | |
| ALKALINE PHOSPHATASE | 70.0 | U/L | 53 - 128 | |

Ratio

U/L

1.5 - 2.5

10.0 - 55.0

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

A/G RATIO

GGTP

MBBS | MD | INCHARGE PATHOLOGY

Page: 2 Of 11

Patient Name Mr. MOHAN LAL MEENA Lab No 4016827 UHID **Collection Date** 09/12/2023 12:56PM 40008253 09/12/2023 1:19PM Age/Gender **Receiving Date** 44 Yrs/Male Report Date O-OPD **IP/OP Location** 09/12/2023 5:45PM

Referred By Dr. DIWANSHU KHATANA Report Status Final

Mobile No. 9610884892

BIOCHEMISTRY

BILIRUBIN TOTAL: - Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILLRUBIN DIRECT: - Method: Diazo method Interpretation: - Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Biver colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

Cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

| TOTAL CHOLESTEROL | 243 | | <200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High |
|-----------------------|-------|-------|--|
| HDL CHOLESTEROL | 43.6 | | High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female) |
| LDL CHOLESTEROL | 167.0 | | Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl |
| CHOLESTERO VLDL | 44 | mg/dl | 10 - 50 |
| TRIGLYCERIDES | 221.5 | | Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl |
| CHOLESTEROL/HDL RATIO | 5.6 | % | |

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. MOHAN LAL MEENA Lab No 4016827 UHID 40008253 **Collection Date** 09/12/2023 12:56PM 09/12/2023 1:19PM Age/Gender 44 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 09/12/2023 5:45PM

Referred By Dr. DIWANSHU KHATANA **Report Status** Final

Mobile No. 9610884892

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation: -The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

| UREA | 15.20 L | mg/dl | 16.60 - 48.50 |
|------------|---------|--------|---------------|
| BUN | 7.1 | mg/dl | 6 - 20 |
| CREATININE | 0.58 L | mg/dl | 0.60 - 1.10 |
| SODIUM | 138.6 | mmol/L | 136 - 145 |
| POTASSIUM | 4.24 | mmol/L | 3.50 - 5.50 |
| CHLORIDE | 98.7 | mmol/L | 98 - 107 |
| URIC ACID | 5.6 | mg/dl | 3.5 - 7.2 |
| CALCIUM | 9.63 | mg/dl | 8.60 - 10.30 |

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. MOHAN LAL MEENA Lab No 4016827 UHID 40008253 **Collection Date** 09/12/2023 12:56PM 09/12/2023 1:19PM Age/Gender **Receiving Date** 44 Yrs/Male Report Date O-OPD **IP/OP Location** 09/12/2023 5:45PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final

Mobile No. 9610884892

CREATININE - SERUM :- Method: -Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.

POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

RESULT ENTERED BY : SUNIL EHS

Patient Name Mr. MOHAN LAL MEENA Lab No 4016827 UHID 40008253 **Collection Date** 09/12/2023 12:56PM 09/12/2023 1:19PM Age/Gender **Receiving Date** 44 Yrs/Male **Report Date IP/OP Location** O-OPD 09/12/2023 5:45PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final

Mobile No. 9610884892

BLOOD BANK INVESTIGATION

Biological Ref. Range Test Name Result Unit

"AB" Rh Positive **BLOOD GROUPING**

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Lab No 4016827 Mr. MOHAN LAL MEENA **Collection Date** 09/12/2023 12:56PM UHID 40008253 09/12/2023 1:19PM Age/Gender **Receiving Date** 44 Yrs/Male **Report Date** O-OPD **IP/OP Location** 09/12/2023 5:45PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final

Mobile No. 9610884892

CLINICAL PATHOLOGY

| Test Name | Result | Unit | Biological Ref. Range | |
|-----------------------------|-------------|------|-----------------------|---------------|
| URINE SUGAR (POST PRANDIAL) | | | | Sample: Urine |
| URINE SUGAR (POST PRANDIAL) | NEGATIVE | | NEGATIVE | |
| | | | | |
| URINE SUGAR (RANDOM) | | | | Sample: Urine |
| URINE SUGAR (RANDOM) | NEGATIVE | | NEGATIVE | |
| | | | | |
| | | | | Sample: Urine |
| PHYSICAL EXAMINATION | | | | |
| VOLUME | 40 | ml | | |
| COLOUR | PALE YELLOW | | P YELLOW | |
| APPEARANCE | CLEAR | | CLEAR | |
| CHEMICAL EXAMINATION | | | | |
| PH | 5.0 L | | 5.5 - 7.0 | |
| SPECIFIC GRAVITY | 1.005 | | 1.016-1.022 | |
| PROTEIN | NEGATIVE | | NEGATIVE | |
| SUGAR | NEGATIVE | | NEGATIVE | |
| BILIRUBIN | NEGATIVE | | NEGATIVE | |
| BLOOD | NEGATIVE | | | |
| KETONES | NEGATIVE | | NEGATIVE | |
| NITRITE | NEGATIVE | | NEGATIVE | |
| UROBILINOGEN | NEGATIVE | | NEGATIVE | |
| LEUCOCYTE | NEGATIVE | | NEGATIVE | |
| MICROSCOPIC EXAMINATION | | | | |
| WBCS/HPF | 0-1 | /hpf | 0 - 3 | |
| RBCS/HPF | 0-0 | /hpf | 0 - 2 | |
| EPITHELIAL CELLS/HPF | 0-2 | /hpf | 0 - 1 | |
| CASTS | NIL | | NIL | |
| CRYSTALS | NIL | | NIL | |
| | | | | |

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

Mr. MOHAN LAL MEENA **Patient Name** Lab No 4016827 UHID 40008253 **Collection Date** 09/12/2023 12:56PM 09/12/2023 1:19PM Age/Gender 44 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 09/12/2023 5:45PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final 9610884892 Mobile No.

CLINICAL PATHOLOGY

NIL **BACTERIA** NIL **OHTERS** NIL NIL

Methodology:-

Methodology:Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific
Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue
(Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method.
interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. MOHAN LAL MEENA Lab No 4016827 UHID 40008253 **Collection Date** 09/12/2023 12:56PM Age/Gender 09/12/2023 1:19PM 44 Yrs/Male **Receiving Date** Report Date **IP/OP Location** O-OPD 09/12/2023 5:45PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final

Mobile No. 9610884892

HEMATOLOGY

| Test Name | Result I | Jnit | Biological Ref. Rai | nge |
|------------------------------|----------|----------------|---------------------|--------------------------|
| CBC (COMPLETE BLOOD COUNT) | | | | Sample: WHOLE BLOOD EDTA |
| HAEMOGLOBIN | 13.7 | g/dl | 13.0 - 17.0 | |
| PACKED CELL VOLUME(PCV) | 41.1 | % | 40.0 - 50.0 | |
| MCV | 107.6 H | fl | 82 - 92 | |
| МСН | 35.9 H | pg | 27 - 32 | |
| MCHC | 33.3 | g/dl | 32 - 36 | |
| RBC COUNT | 3.82 L | millions/cu.mm | 4.50 - 5.50 | |
| TLC (TOTAL WBC COUNT) | 7.59 | 10^3/ uL | 4 - 10 | |
| DIFFERENTIAL LEUCOCYTE COUNT | | | | |
| NEUTROPHILS | 64.5 | % | 40 - 80 | |
| LYMPHOCYTE | 27.7 | % | 20 - 40 | |
| EOSINOPHILS | 2.2 | % | 1 - 6 | |
| MONOCYTES | 5.5 | % | 2 - 10 | |
| BASOPHIL | 0.1 L | % | 1 - 2 | |
| PLATELET COUNT | 1.84 | lakh/cumm | 1.500 - 4.500 | |

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV: - Method: - Calculation bysysmex.

MCH: - Method: - Calculation bysysmex.

MCHC: - Method: - Calculation bysysmex.

MCHC: - Method: - Calculation bysysmex.

REC COUNT: - Method: - Hydrodynamicfocusing.Interpretation: - Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry LYMPHOCYTS :- Method: Optical detectorblock based on Flowcytometry EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 15 mm/1st hr 0 - 15

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Lab No Mr. MOHAN LAL MEENA 4016827 UHID 40008253 **Collection Date** 09/12/2023 12:56PM 09/12/2023 1:19PM Age/Gender **Receiving Date** 44 Yrs/Male **Report Date** O-OPD **IP/OP Location** 09/12/2023 5:45PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final Mobile No. 9610884892

Method:-Modified Westergrens. Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : SUNIL EHS

Page: 10 Of 11

Mr. MOHAN LAL MEENA **Patient Name** Lab No 4016827 UHID 40008253 **Collection Date** 09/12/2023 12:56PM 09/12/2023 1:19PM Age/Gender **Receiving Date** 44 Yrs/Male **Report Date IP/OP Location** O-OPD 09/12/2023 5:45PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final Mobile No. 9610884892

X Ray

Test Name Result Unit Biological Ref. Range

X-RAY CHEST P. A. VIEW

Both lung fields are clear.

Both CP angles are clear.

Both hemi-diaphragms are normal in shape and outlines.

Cardiac shadow is within normal limits.

Visualized bony thorax is unremarkable.

Correlate clinically& with other related investigations.

End Of Report

RESULT ENTERED BY : SUNIL EHS

Adven

APOORVA JETWANI

Select

Page: 11 Of 11